Fetal growth restriction is associated with reduced FasL expression by decidual cells
- PMID: 17196256
- DOI: 10.1016/j.jri.2006.11.002
Fetal growth restriction is associated with reduced FasL expression by decidual cells
Abstract
The Fas-Fas ligand (FasL) system contributes to immune tolerance at the feto-maternal site and has been ascribed a role in implantation and placental development by regulating trophoblast invasion and spiral artery remodelling. In the present study, we have examined FasL expression in decidual tissue from pregnancies with impaired placental development. Women with pre-eclampsia (PE) and/or fetal growth restriction (FGR) were enrolled as cases (n=33), and women with normal pregnancies were used as controls (n=27). Decidua basalis tissue was obtained by vacuum suction of the placental bed after delivery. FasL expression by extravillous trophoblasts (EVTs) and decidual cells (DeCs), together with EVT apoptosis, were assessed by immunohistochemistry. Levels of soluble FasL in maternal serum and apoptosis-related gene expression in decidual tissue were determined. The proportion of FasL-expressing DeCs was high in controls (72.0+/-10.2%), with a significant reduction among cases (58.1+/-19.7%; p=0.002), especially in those with FGR (54.3+/-19.9%; p<0.001). EVTs had a lower proportion of FasL expression than DeCs, with a less pronounced reduction in cases compared to controls (10.9+/-3.9 and 8.3+/-4.0%, respectively; p=0.02). Decidual FasL expression correlated with placental growth. The EVT apoptosis rate did not differ between cases and controls (1.1+/-1.9 and 1.1+/-1.3%, respectively). These findings indicate a reduction of immune privilege in decidua of PE/FGR pregnancies by reduced FasL expression and that DeCs may have a central role in the Fas-FasL-based feto-maternal immune balance.
Similar articles
-
Matrix metalloproteinase 1 in pre-eclampsia and fetal growth restriction: reduced gene expression in decidual tissue and protein expression in extravillous trophoblasts.Placenta. 2010 Jul;31(7):615-20. doi: 10.1016/j.placenta.2010.04.003. Epub 2010 May 8. Placenta. 2010. PMID: 20452670
-
Aberrant expression of corticotropin-releasing hormone in pre-eclampsia induces expression of FasL in maternal macrophages and extravillous trophoblast apoptosis.Mol Hum Reprod. 2012 Nov;18(11):535-45. doi: 10.1093/molehr/gas027. Epub 2012 Jul 4. Mol Hum Reprod. 2012. PMID: 22763913
-
Placental apoptosis and adhesion molecules expression in the placenta and the maternal placental bed of pregnancies complicated by fetal growth restriction with and without pre-eclampsia.J Obstet Gynaecol. 2006 Jan;26(1):5-10. doi: 10.1080/01443610500363840. J Obstet Gynaecol. 2006. PMID: 16390700
-
The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces.Semin Reprod Endocrinol. 1999;17(1):39-44. doi: 10.1055/s-2007-1016210. Semin Reprod Endocrinol. 1999. PMID: 10406074 Review.
-
Apoptosis and its role in the trophoblast.Am J Obstet Gynecol. 2006 Jul;195(1):29-39. doi: 10.1016/j.ajog.2005.07.039. Epub 2006 Mar 31. Am J Obstet Gynecol. 2006. PMID: 16579915 Review.
Cited by
-
Innate Lymphoid Cells at the Maternal-Fetal Interface in Human Pregnancy.Int J Biol Sci. 2020 Jan 30;16(6):957-969. doi: 10.7150/ijbs.38264. eCollection 2020. Int J Biol Sci. 2020. PMID: 32140065 Free PMC article. Review.
-
Maternal circulating concentrations of soluble Fas and Elabela in early- and late-onset preeclampsia.J Matern Fetal Neonatal Med. 2022 Jan;35(2):316-329. doi: 10.1080/14767058.2020.1716720. Epub 2020 Feb 2. J Matern Fetal Neonatal Med. 2022. PMID: 32008387 Free PMC article.
-
Increased plasma levels of CK-18 as potential cell death biomarker in patients with HELLP syndrome.Cell Death Dis. 2013 Oct 24;4(10):e886. doi: 10.1038/cddis.2013.408. Cell Death Dis. 2013. PMID: 24157880 Free PMC article.
-
FAS and FAS-L genotype and expression in patients with recurrent pregnancy loss.Reprod Sci. 2013 Sep;20(9):1111-5. doi: 10.1177/1933719113477488. Epub 2013 Feb 18. Reprod Sci. 2013. PMID: 23420824 Free PMC article.
-
Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.Int J Mol Sci. 2021 May 18;22(10):5302. doi: 10.3390/ijms22105302. Int J Mol Sci. 2021. PMID: 34069909 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous